Galderma Group N (GALD.SW)
CHF 96.0
(1.12%)
CHF 96.0
(1.12%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 3.46 Billion | 3.59 Billion | 3.12 Billion |
| Cost of Revenue | 1.03 Billion | 1.14 Billion | 945.26 Million |
| Gross Profit | 2.42 Billion | 2.45 Billion | 2.17 Billion |
| Operating Expenses | 1.97 Billion | 2.12 Billion | 1.87 Billion |
| Selling, General and Administrative Expenses | 1.67 Billion | 1.82 Billion | 1.56 Billion |
| Research and Development Expenses | 241.3 Million | 301.7 Million | 313.22 Million |
| Other Expenses | 63.24 Million | - | - |
| Cost and Expenses | 3.01 Billion | 3.26 Billion | 2.82 Billion |
| Operating Income | 450.56 Million | 327.01 Million | 300.88 Million |
| Interest Expense | 503.96 Million | 378.2 Million | 320.81 Million |
| Income Tax Expense | 57.27 Million | 42.97 Million | 4.11 Million |
| Earnings before Tax | 9.16 Million | -49.56 Million | -72.86 Million |
| Net Income | -48.1 Million | -94.07 Million | -141.07 Million |
| Earnings Per Share Basic | -0.01 | -0.40 | -0.59 |
| Earnings Per Share Diluted | -0.01 | -0.40 | -0.59 |
| Weighted Average Shares Outstanding | 5.68 Billion | 237.56 Million | 237.56 Million |
| Weighted Average Shares Outstanding (Diluted) | 5.68 Billion | 237.56 Million | 237.56 Million |
| Gross Margin | 0.70 | 0.68 | 0.70 |
| EBIT Margin | 0.20 | 0.16 | 0.17 |
| Profit Margin | -0.01 | -0.03 | -0.05 |
| EBITDA | 690.44 Million | 592.23 Million | 476.05 Million |
| Earnings Before Tax Margin | 0.13 | 0.09 | 0.10 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Revenue | 995.34 Million | 999.28 Million | 3.66 Billion | 1.84 Billion | 1.82 Billion | 921.64 Million |
| Cost of Revenue | 299.59 Million | 300.77 Million | 1.1 Billion | 573.62 Million | 532.63 Million | 267.11 Million |
| Gross Profit | 695.75 Million | 698.5 Million | 2.56 Billion | 1.26 Billion | 1.29 Billion | 654.52 Million |
| Operating Expenses | 555.16 Million | 556.45 Million | 2.04 Billion | 1 Billion | 1.03 Billion | 527.37 Million |
| Selling, General and Administrative Expenses | 494.08 Million | 496.03 Million | - | 876.32 Million | 909.31 Million | 456.47 Million |
| Research and Development Expenses | 60.63 Million | 60.87 Million | - | 132.71 Million | 124.95 Million | 62.66 Million |
| Other Expenses | 449.16 Thousand | - | - | - | - | - |
| Cost and Expenses | 854.76 Million | 857.23 Million | 3.15 Billion | 1.58 Billion | 1.56 Billion | 794.48 Million |
| Operating Income | 140.58 Million | 142.04 Million | 517.71 Million | 257.72 Million | 259.93 Million | 135.38 Million |
| Interest Expense | 217.07 Million | - | 503.96 Million | 233.55 Million | 271.79 Million | - |
| Income Tax Expense | 13.47 Million | 13.52 Million | 61.19 Million | 78.88 Million | -19.15 Million | 9.6 Million |
| Earnings before Tax | 34.58 Million | 34.72 Million | 9.79 Million | 24.7 Million | -15.5 Million | -7.77 Million |
| Net Income | 21.11 Million | 21.19 Million | -51.4 Million | -54.18 Million | 3.64 Million | 1.82 Million |
| Earnings Per Share Basic | 0.09 | 0.09 | - | -0.23 | 0.02 | 0.01 |
| Earnings Per Share Diluted | 0.09 | 0.09 | - | -0.23 | 0.02 | 0.01 |
| Weighted Average Shares Outstanding | 237.56 Million | 237.56 Million | 237.56 Million | 237.56 Million | 237.56 Million | 237.58 Million |
| Weighted Average Shares Outstanding (Diluted) | 237.61 Million | 237.61 Million | 237.56 Million | 237.56 Million | 237.56 Million | 237.56 Million |
| Gross Margin | 0.70 | 0.70 | 0.70 | 0.69 | 0.71 | 0.71 |
| EBIT Margin | 0.19 | 0.19 | - | 0.21 | 0.21 | 0.20 |
| Profit Margin | 0.02 | 0.02 | -0.01 | -0.03 | 0.00 | 0.00 |
| EBITDA | 188.64 Million | 189.39 Million | - | 385.57 Million | 380.32 Million | 182.49 Million |
| Earnings Before Tax Margin | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.15 |
CHOICEIN
301206
DKL
TKPHF
300158
BEKE